All In MedTech

Device Trial Radar · NCT07947485

Six-Channel Wearable ECG for Prediction of Hyperkalemia in Hemodialysis Patients

Prediction of Hyperkalemia in Hemodialysis Patients Through Waveform Analysis Using a Six-Channel Wearable Electrocardiogram

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 12, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Chungnam National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Korea Health Industry Development Institute
First posted
Nov 19, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 19 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hyperkalemia is a common and potentially fatal electrolyte disorder in patients receiving maintenance hemodialysis, but it is currently detected only by periodic blood tests. This prospective, single-center observational cohort study will evaluate whether T-wave morphology measured with a six-channel wearable electrocardiogram (ECG) patch can identify hyperkalemia (serum potassium greater than 5.0 mEq/L) in these patients. Forty adults on thrice-weekly hemodialysis will wear the device during one dialysis session per month for 6 months. ECG recordings will be compared with serum potassium measured before and after the same dialysis session. No treatment is assigned by the study, and no additional blood draws are required.

Conditions

  • Hyperkalemia
  • End-Stage Kidney Disease (ESKD)
  • Hemodialysis

Interventions

  • Six-channel wearable ECG patch (SHC-U8)Device

    A wearable Holter-type ECG recorder (model SHC-U8, Solmitech Co., Ltd., Republic of Korea) that records six ECG channels from three chest electrodes. The device is attached immediately before dialysis and removed at the end of the session, once per month for 6 months. It is used within its approved indication for ECG recording only; no treatment is assigned.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the receiver operating characteristic curve (AUC) of the pre-dialysis T-wave morphology index for discriminating hyperkalemiaTime frame: At each monthly dialysis session for 6 months (6 sessions per participant)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chungnam National University Hospital

    Daejeon, DJ, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.